Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

731.33 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 235
Open 731.33
Bid (Size) 730.00 (1)
Ask (Size) 734.13 (1)
Prev. Close 731.33
Today's Range 731.33 - 731.33
52wk Range 370.68 - 800.78
Shares Outstanding N/A
Dividend Yield 0.62%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires Manufacturing Facility From Nexus Pharma
Eli Lilly expands its global manufacturing network with FDA-approved facility acquisition in Pleasant Prairie, Wisconsin. Boosting production to meet growing demand for medicines, including GLP-1... 
Via Benzinga
7 High-Flying Stocks That Are Majorly Overdue for a Pullback
After performing strongly since the start of the year, it's time to sell these stocks due for a pullback before they reverse course. 
Via InvestorPlace

Performance

YTD
+23.49%
+23.49%
1 Month
-5.41%
-5.41%
3 Month
+15.92%
+15.92%
6 Month
+26.82%
+26.82%
1 Year
+90.77%
+90.77%

More News

Read More
Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending
Via Benzinga
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
Via MarketBeat
Exploring The Competitive Space: Eli Lilly and Co Versus Industry Peers In Pharmaceuticals
Via Benzinga
Eli Lilly and Co's Options Frenzy: What You Need to Know
Via Benzinga
6 Stocks Positioned to Soar as Investors Focus on MASH
Via TheNewswire.com
Capturing Consumer Spending on Health Care with XLV
Via News Direct
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
Via The Motley Fool
3 Relatively Safe Growth Stocks You Can Buy and Hold
Via The Motley Fool
SPDR ETF Report For Friday, April 19
Via Talk Markets
Topics ETFs
Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Strong Buy Alert: 7 No-Brainer Stocks to Scoop Up Now
Via InvestorPlace
Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025
Via Benzinga
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 15 Years
Via Benzinga
Want to Double Your Tax Refund in 2024? 7 Stocks to Buy Now.
Via InvestorPlace
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
Via AB Newswire
Topics Economy
Exposures Interest Rates
2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years
Via The Motley Fool
Top Research Reports For Eli Lilly, Linde & Caterpillar
Via Talk Markets
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
Via The Motley Fool
Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test
Via Investor's Business Daily
Nasdaq 100 Forecast: QQQ Inches Higher Ahead Of Fed Speakers
Via Talk Markets
Topics Economy
Exposures Interest Rates
Eli Lilly's Famed Weight Loss Drug Zepbound Works As Sleep Apnea Treatment, Successful Late-Stage Studies Show
Via Benzinga
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
Via InvestorPlace
Topics ETFs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.